Glycemic And Patient-Reported Outcomes After Transition To Advanced Hybrid Closed-Loop System In Patients After Total Pancreatectomy

Clicks: 8
ID: 338049
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #440 of 449 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 449 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVE: To evaluate glycemic and patient-reported outcomes associated with transition from multiple daily injections (MDI) to Advanced Hybrid Closed-Loop (AHCL) therapy in adults with diabetes shortly after total pancreatectomy (TP). RESEARCH DESIGN AND METHODS: In this single-center prospective observational study, 15 adults with diabetes after TP transitioned from MDI to AHCL therapy. The prespecified primary outcome was time in range (TIR; 70-180 mg/dL) during the first month of AHCL compared with the last month of MDI. Secondary outcomes included other continuous glucose monitoring (CGM) metrics, hypoglycemic events, and patient-reported outcomes; CGM outcomes were followed for 6 months. An exploratory comparison was also performed with 28 patients who remained on MDI. RESULTS: Median TIR increased from 53.9% to 72.0% (P < 0.01). TAR, mean glucose, GRI, and coefficient of variation also decreased (all P < 0.05), and CGM outcomes remained broadly stable throughout the 6-month follow-up. TBR and hypoglycemic-event frequency did not differ significantly. Median hypoglycemic-event duration decreased from 55.2 to 35.0 minutes (P < 0.01). Anxiety and fear of hypoglycemia decreased while other patient reported outcomes did not change significantly. In an exploratory comparison, AHCL recipients had higher TIR and lower GRI than 28 patients who remained on MDI. CONCLUSIONS: In this selected cohort, transition to AHCL was associated with improved TIR and favourable changes in CGM-derived glycemic outcomes, without a significant increase in TBR. These exploratory findings suggest that AHCL may be a feasible therapeutic option for selected adults with diabetes after TP. Larger controlled studies are needed to confirm its clinical benefits and long-term sustainability.
Reference Key
openalex_W7224854389 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Giona Castagna, Nicolò Diego Borella, Giuseppe Lepore, Michela Vergani, Lucrezia Zanchi, Michela Guizzetti, Domenico Pinelli, Roberto Trevisan
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag431
URL
https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgag431/72614492/dgag431.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.